Penumbra, Inc. (PEN) Earnings Call Transcript & Summary
August 3, 2020
Earnings Call Speaker Segments
Jee Hamlyn-Harris
executiveThanks, operator, and I appreciate everyone being with us today as we go over Penumbra's results for the second quarter of 2020. You can find the press release and the financial tables, which contain a reconciliation from GAAP to non-GAAP, on the Investors section of our website, www.penumbrainc.com. On this call, we'll be making forward-looking statements under the safe harbor protections of the Private Securities Litigation Reform Act of 1995, covering things like our financial performance, commercialization efforts, clinical trials, regulatory status, quality, compliance, and business trends. Actual outcomes may differ materially from what those statements state or suggest, because of various risks and uncertainties, such as the ones cited in our 10-Q for the quarter that ended June 30, 2020, set to be submitted to the SEC on August 3, 2020, and the ones laid out in our 10-K for the year that ended December 31, 2019, filed with the SEC on February 26, 2020. So we urge you not to put excessive weight on these forward-looking statements, and we suggest you look at our periodic SEC filings, including the 10-Q and 10-K just referenced, for a fuller picture of these factors and other risks that could influence our future results or the market price of our stock, such as, though not limited to, how the COVID-19 pandemic affects our business, results of operations, and financial conditions. Penumbra accepts no obligation to update or revise our forward-looking statements because of new information, future events, developments, or anything else. Some financial measures on this call are given on a non-GAAP basis. A reconciliation between GAAP and non-GAAP financial measures appears in the press release we posted. We expect the prepared remarks today to take about 19 minutes. Adam Elsesser, Penumbra's Chairman and CEO, will give a business update. Maggie Yuen, our Chief Financial Officer, will follow with a discussion of our financial results for the quarter. Jason Mills, our Executive Vice President of Strategy, will be with Adam and Maggie for Q&A. With that, I'll hand the call over to Adam Elsesser.
Adam Elsesser
executiveThanks, Jee, and good afternoon to everyone. I appreciate you being on Penumbra's call for the second quarter of 2020. Revenue across the company came to $105.1 million for Q2, which represents a decline of 21.7% versus the prior year on a reported basis and 21.3% when measured in constant currency. Maggie is going to walk through the financial details more thoroughly, along with additional information about our balance sheet and her thoughts. There are 3 separate subjects I want to cover in what I say today: first, the challenges resulting from the COVID-19 pandemic and how we see the path ahead; second, what has happened since our previous earnings call regarding the company overall and our individual products; and last, the matter of racial injustice that emerged during this past quarter and the way Penumbra is responding to it, both inside the organization and outside it. To begin, as we mentioned during our prior earnings call, Penumbra's initial response to the COVID-19 pandemic was to guarantee that every one of our employees was able to work in safety. During the last several months, we have kept refining the way we run things, specifically how we produce our products and how we engage with our customers. When it comes to producing products, our team has performed remarkably well in delivering on 2 central goals: maintaining a safe work environment and meeting demand. On the broader business front, we have likewise concentrated on cutting costs in every instance where it was feasible and sensible. Regarding customers, we are quite happy with how well our team has managed to deepen those relationships through this difficult period, including what may be the most successful launch of a new product in Penumbra's history, about which I will say more shortly. Now that these significant structural changes are in place, we hold substantial confidence that our team will keep operating effectively for the full duration of this pandemic. Let me now describe a number of the particular revenue figures and patterns from the quarter. Throughout our business as a whole, we observed steady gains as the quarter went on. To be specific, within markets where we sell directly, our business reached just under 90% of pre-COVID levels during the quarter's latter half. In fact, June's trends were superior even to that. As a point of recollection, we noted last quarter that the share of our international business managed by distributors, most of which consists of our stroke products, came with greater uncertainty last quarter owing to the pandemic, since our distributors were attempting to find their way through the crisis and its effects on their own operations. That said, this does not create worry regarding our long-term business prospects in those regions once we move past the pandemic. Despite our encouraging June recovery, we believe the quickening spread of the COVID-19 virus within the United States and other areas of the world where our products are sold gives us reason for caution when it comes to extending late Q2 trends into the year's second half. Let me be upfront about this, though: we don't think the way COVID-19 has shaken up our revenue patterns ought to shift us away in any fundamental sense from where our medical device competitors generally land on revenue. Looking past the figures, Penumbra's people gave tremendous effort during Q2 to steer this company through this stretch of the pandemic, and we'll come out of it in an even better position. Also, even though COVID-19 will keep throwing obstacles at us, I have no doubt that Penumbra's culture equips our team to face this confidently, staying steadily focused on what counts for our physicians and for the patients under their care. Let me turn to topic number two now. News on the company and on our product lineup since the previous call. Some might find this surprising, but the past 3 months rank among the most productive stretches in Penumbra's history. To start, we strengthened a balance sheet that was already in good shape during Q2; on top of the $100 million revolving line of credit we previously announced with JPMorgan, Bank of America and Citibank, which remains undrawn. During late May, we completed a follow-on offering that brought in roughly $135 million for the company. Our view is that these moves were sensible means of opening up extra capital access, letting us both get through the present conditions and keep putting money into worthwhile opportunities. Notably, thanks to this financing, we've been at ease speeding up 3 internal development programs that already existed. One among those 3 involves fresh possibilities for the real system that have come about straight out of this pandemic. As for the remaining 2, we haven't made them public. On top of that, we brought in more leadership talent, adding to a leadership team that was already strong and deep, and working alongside them genuinely makes me proud. To be specific, in the middle of May, we brought Jason Mills aboard as Penumbra's Executive Vice President of Strategy. Several weeks back, we made known the selection of Dr. Corey Teigen as Chief Scientific Officer along with Dr. Jim Benenati as Chief Medical Officer; 2 positions that are brand new. This is a perfect moment to bring Jason, Corey and Jim onto Penumbra's leadership team as we enter our next stage of growth; at this point I'd like to walk through a handful of product developments from the first half of 2020 that strike me as highly significant for Penumbra. At our December Investor Day, we said we anticipated 1 stroke and 2 peripheral thrombectomy products getting FDA clearance during 2020. Each of those 3 products got cleared within the first half of the year. We also obtained clearance for a neuro access product. In our view, the stroke product and the neuro access product alike are key pieces of our upcoming stroke development efforts, which we anticipate arriving in 2021. Turning to the peripheral thrombectomy products, we announced the U.S. launch of 2 remarkable products on Tuesday, July 14. When these 2 products are paired, they create the Lightning 12 system — a major leap forward in the way clot is taken out of the body. The manner in which we brought Lightning 12 to market deserves attention. This groundbreaking system was released via an innovative virtual event that achieved enormous reach and generated favorable engagement from physicians. In fact, going forward this could turn into our go-to approach for introducing significant new offerings. Allow me a moment to lay out the new Lightning 12 paradigm, since we believe communicating how distinctive this technology is matters greatly. Within the Lightning 12 system there is a newly designed, bigger aspiration catheter that uses cutting-edge laser cut hypotube catheter engineering, delivering superior deliverability and torquability inside the body; this distinctive larger catheter gets paired with Lightning, intelligent aspiration tubing, which may be the single most inventive and technologically sophisticated product our vascular franchise has ever created. Through proprietary sophisticated software algorithms, Lightning automates blood clot detection and tells clot apart from flowing blood, letting physicians concentrate on maximizing thrombus removal while lessening worry about blood loss. Putting these 2 products together gives Lightning 12 the title of Penumbra's most advanced clot removal technology. Physician feedback has been extremely favorable and deeply inspiring for all of us on the team. Take Lexington, Kentucky, where Dr.
Adam Elsesser
executiveA patient was brought to Nick Abedi's attention, so he got in touch with the territory manager in our area. She was a young woman, 36 weeks into her pregnancy, whose left leg contained a blood clot filling it completely — it began just behind the knee and ran the full distance up to the common iliac vein. For this patient, then, the venous side carried a truly massive clot burden. Dr. Abedi had recently become aware of Lightning 12, and in particular of a unique thing the system can do: it produces audible signals that tell the physician whether or not the catheter is positioned inside clot. As he saw it, that feature would make the procedure much faster, cutting radiation exposure and blood loss dramatically — important for anyone, but vital in a pregnant patient. In this instance, he used Lightning 12 and was able to pull out the clot. In fact, during a phone conversation we had not long ago, Dr. Abedi told me that no one he had ever treated had yielded this much clot. For such a tough case, that result was superb; in another instance, a man arrived at a Florida hospital suffering from both acute and chronic thrombus in his right brachiocephalic vein. Because Florida right now is a COVID hotspot, all of the ICU beds at that hospital were taken at the time he came in. So administering TPA by drip across several days while he stayed in the ICU could not be done. Dr. At the Lakeland Vascular Institute, Venkat Tummala had a case where the person needed treatment and same-day discharge. Dr. Tummala reached out to our territory manager in the area, requesting that Lightning 12 be brought in for this individual's care. Just 45 minutes were required for the procedure, and blood loss was minimal. An even more encouraging detail: a patient who had been unable to form a fist beforehand could bend their fingers immediately after Dr. Tummala completed clot removal; on top of that, thanks to both Dr. Tummala's expertise and Lightning 12, this person went home that very day. Dr. During a phone conversation we had not long ago, Tummala shared his view that Lightning 12 represents a breakthrough for addressing substantial clot burden on the venous side, doing so without requiring lytics. Only 2 of the initial cases so far demonstrate the shift in approach that Lightning 12 is delivering to this area. Our whole engineering team has my deepest pride for the remarkable effort they put into this product. Last, I want to address how Penumbra has been affected by the nationwide conversation around racial injustice. A great many of our staff voiced a powerful wish to take part in a productive dialogue as a way to direct the shared anger, frustration and distress. That momentum resulted in a plan that spans the whole company, one that covers chances for each person to learn and contribute, plus particular programs inside the company, outside efforts, and outreach to the community. Because the people working here come from so many different backgrounds, Penumbra already has enormous strength, creativity, and capability. My view, though, is that this work will make Penumbra even more capable and stronger as we continue chasing our aim of discovering, developing, and delivering therapies that truly matter to patients. Finally, despite all the disruption and uncertainty caused by the pandemic, Penumbra's long-term growth prospects have never looked better. We are at the earliest point of 2 product launches that matter enormously. Our pipeline and product portfolio are the most robust they have been at any point in our history. The team we have now is the strongest we have ever assembled, and last of all, this crisis is sharpening that team's abilities through relentless commitment, collaboration, and hard work. At this point I will hand the call over to Maggie.
Maggie Yuen
executiveThanks, Adam. Good afternoon, everyone. For Q2, which closed on June 30, 2020, total revenues came to $105.1 million — that's down 21.7% as reported and down 21.3% on a constant currency basis versus the second quarter of 2019. Sales in the quarter broke down geographically as 74% U.S. and 26% international. Neuro accounted for 56% of sales and Vascular 44%. Also, since distributor channels exist only within our international business, we think it's helpful this quarter to give some extra detail on how each of our Vascular and Neuro businesses performed regionally. Our Vascular business brought in $46.3 million in the second quarter of 2020, down 12.1% as reported and 11.9% in constant currency; during the quarter, the decline in Vascular came from results in both our thrombectomy and embolization businesses, each of which felt a heavier negative effect from COVID-19 during the first half of the quarter. The U.S. Vascular business fell 5.7% as reported, while the international Vascular franchise dropped 36.7% as reported versus the second quarter of 2019. Our Neuro business generated $58.8 million in the second quarter of 2020, down 27.8% as reported and 27.3% in constant currency versus the same period a year ago. Our U.S. Neuro business fell 13.3% as reported versus the second quarter of 2019. And the international Neuro franchise dropped 45.4% as reported versus the second quarter of 2019. On a global basis, our Neuro decline was mainly driven by sales of our Penumbra System for ischemic stroke, while distributor order timing affected our international Neuro business. Gross margin for the quarter was 61.8% of revenue, versus 70% of revenue in last year's same quarter. Our second quarter 2020 margin performance reflects volume deleveraging with minimal impact from ASP and product mix. During the quarter, we kept overall manufacturing spending at first quarter 2020 levels, since we made a deliberate choice to keep paying all of our direct labor at 100%, while lowering labor capacity per shift to achieve social distancing and employee safety measures. Because of that, certain labor costs showed up as additional period expense in the quarter. We expect our near-term gross margin to be similar to second quarter levels as we keep balancing volume absorption and investment in capacity expansion and scalability at our new Roseville facility. Total operating expenses for the quarter were $82.6 million, or 78.6% of revenue, versus $81.1 million, or 60.5% of revenue, for the same quarter a year ago, which works out to a sequential cost reduction of just under 10% compared to the first quarter of 2020. Our spend control measures include executives' voluntary salary reduction, certain volume-related expenses and fewer activities, such as travel and entertainment and conferences, all of which drove a 20% spending reduction in SG&A compared to the first quarter of 2020, notwithstanding some accelerated investment in production capacity, commercial digital capabilities, product launches and new product development. Research and development costs came to $22.7 million in Q2 2020, versus $13.5 million in Q2 2019, since we sped up spending on a handful of key long-term growth opportunities for Penumbra that Adam mentioned before. SG&A came in at $59.9 million in Q2 2020, versus $67.7 million in Q2 2019. For the quarter we posted an operating loss of $17.6 million, versus operating income of $12.8 million in the comparable period a year ago. Now moving to cash flow and the balance sheet: we closed the second quarter of 2020 with $278 million of cash and cash equivalents plus marketable securities, and no debt. Net cash rose by $110 million, which reflects roughly $135 million in net cash proceeds from the May secondary offering, partly offset by cash used in operating activities in Q2. Even with our solid balance sheet, we'll keep restraining spending wherever it makes sense to do so amid this uncertain period, while continuing to prioritize innovation and strategic investment. Last, because of the uncertainty the COVID-19 crisis created, we pulled our 2020 guidance in early April. That stance remains in place as of today, since we can't reliably say that the recent patterns in our business point to a recovery, particularly with cases having accelerated lately across the United States and in certain markets worldwide. At this point I'd like to hand the call back to Adam for his closing remarks.
Adam Elsesser
executiveLike Maggie and I already explained, even with the difficulties and the unpredictability caused by the pandemic, Penumbra sits in a solid spot for significant growth over the long haul. In my final comments, I want to state plainly that this strength exists solely thanks to the incredible individuals employed at Penumbra and the phenomenal effort they put in daily. Beyond that, I wish to express my thanks to each Penumbra worker for what you were giving up throughout this extremely tough period. I appreciate it; and at this point we would like to begin the question-and-answer portion of the call.
Bob Hopkins
analystMy first question is really just to clarify what you said regarding the effect of distributor actions in the core and outside the United States. I was wondering — apologies if this was already covered — whether you could put a number on how much this affected the company during Q2? And perhaps help us understand how long you expect it to continue? I'm simply seeking a bit more clarity regarding the remarks you made about distributors.
Adam Elsesser
executiveCertainly. That part of our business was not quantified by us. What we emphasized was the majority — actually the vast majority — of our business, which is direct. Distributors, as you're aware, account for somewhere in the range of 10% to 20% of our business. Therefore the vast majority is not that. And I stated quite clearly that in our view this was not any sort of fundamental situation, but rather just those companies — many being family-owned distributorships — running their own operations through this period. Thus I don't believe there is any kind of long-term effect, beyond managing their business on a quarter-by-quarter basis. And what really deserves attention are the businesses under our control, which is, again, the majority of the business, are revenue.
Bob Hopkins
analystAll right. I was simply curious whether there's any way to quantify how much this affected total revenue during Q2. That said, I understand it's a near-term matter — I was just interested. The second item I'd like to raise with you, Adam, concerns clarifying what you said regarding June and what comes after. To help investors out. Could you tell us Penumbra's company-wide revenue growth rate year-over-year for the month of June, since we have that figure from the majority of MedTech companies? I also want to confirm I understood your remarks about trends following June, since I believe you essentially noted that the spread of COVID has caused a slight slowdown after June, and I just want to be sure I got that right.
Adam Elsesser
executiveYes. Look, I — we — in our prepared remarks, what we did was qualify the back half of the quarter against the front half, meaning the initial 6 weeks against the latter 6 weeks, and then we noted June came in as a slight increase over that. So using figures wasn't intentional on our part. And Bob, I completely grasp the wish to learn about these very granular movements and then, as you mentioned, extend into July, how everything is progressing. I fully understand that. I've even come across some people requesting companies provide something like a week-by-week breakdown of their figures; however, in our view, information you get from watching those sorts of patterns isn't truly dependable. That said, and in the interest of full transparency, our July figures show an even more positive upward movement compared with the earlier ones. But the message I wanted to deliver, and the point we want to emphasize, is genuinely crucial, which is that a rise in cases always functions as an early signal for hospitalization figures, and during July we witnessed an enormous surge in cases. And so it's simply wise, if you consider what mainstream media and public health officials are saying, including just in recent days across the weekend, that when it comes to what lies ahead, predicting where this heads is difficult. We have no information. Nothing about our business is fundamentally different from our MedTech peers, which is a point we wanted to make. But projecting out to the end of this quarter isn't wise for us, even the strong beginning of this — of quarter 2, or any trends across the full quarter, given how this is unfolding. So we simply wanted to be absolutely clear, again, we have performed well. We've witnessed a pleasant uptick. But we believe, just as our peers are stating, that we cannot forecast how this goes for the remainder of the year.
Bob Hopkins
analystAll right, so I suppose the takeaway is — and I'm sorry these questions are so focused on the near term, but the situation is simply unlike anything else. So I suppose the takeaway is that July comes out ahead of June, yet don't read too much into that, given how much uncertainty there is.
Adam Elsesser
executiveCorrect.
Cecilia Furlong
analystGreat. So, Adam, I'd like to begin, if I may, by getting your big-picture take on the peripheral market and DVT now that Lightning is in the picture — specifically, how much of a role can technology innovation play versus clinical data when it comes to growing that market? And are there any market differences worth pointing out compared with what you saw in stroke?
Adam Elsesser
executiveYes. I appreciate the question. It's a good one. If I draw the comparison with stroke, what happened there is that the market couldn't really open up until clinical trials from a number of years back demonstrated that treating these patients was the right thing to do in the first place — that was the single most critical piece. Then there's a second job we're still working on, which is ensuring that stroke patients actually reach a hospital capable of treating them. The peripheral market looks dramatically different in how it's presenting itself. At our Investor Day in December, we laid out that over 400,000 patients in the U.S. are right now receiving treatment for their clot — most often through an interventional delivery of TPA, or TPA combined with devices, or else surgically by vascular surgeons — and many of these are already being treated interventionally. So these patients are already getting treated despite there being no clinical data supporting that treatment. Suppose you ran clinical work proving, say in PE or DVT, that using some of these newer modern techniques — Lightning 12 in particular — outperformed what amounts to the original standard of care, namely medical management; you could then take that 420,000 or 430,000 figure and move it to a far bigger number, likely reaching 600,000 or 700,000 plus. And again, all of these patients are already being treated in the very same labs where our customers are using Lightning 12. So clinical work definitely lies ahead of us in our plans, but its real purpose is expanding the market beyond those 430,000 patients rather than capturing that initial large market.
Cecilia Furlong
analystGreat. And I suppose, could I ask you to expand on what you said about the advantages you experienced during the quarter from doing this launch in a virtual manner? But more importantly, how are you approaching product launches from here on out? What advantages stood out most? And what about your ability to truly make that workflow more efficient?
Adam Elsesser
executiveWell, yes — I appreciate the question. Some of our specific approach I'll hold back, even if it has become somewhat apparent, since I don't want competitors turning it to their advantage; however, I can say that adjusting and responding to circumstances as they change is fairly remarkable. Our people figured out how to genuinely connect, leveraging the available tools and being highly inventive in our approach, so that details concerning this product reached the market within a far shorter period. Typically, with a product launch, you begin and your sales force begins scheduling meetings, phoning physicians, and then sitting down with them. That approach has been well tested and it succeeds, yet a specific duration is required. Thanks to the methods we employed for this launch and the character of the moment, we managed to compress a portion of that duration quite substantially. Whether it would work equally well outside a pandemic setting is difficult to determine. It could continue to provide value past this situation, or it might not, yet for this launch it was undeniably highly effective for us. And without trying to be clever, the fact that this product performs as well as it does certainly helps, since it truly is a rather remarkable product.
Larry Biegelsen
analystAdam, I'm guessing the item you mentioned—the one you called the greatest launch we've ever had—is the new Indigo 12 French with Lightning. Is that right?
Adam Elsesser
executiveYes. Yes.
Larry Biegelsen
analystAlright, so you rolled this out on July 14, and it's still quite soon to be saying that. So I suppose I have a few questions about it. First, what is that statement founded on? And we're figuring we've picked up in the marketplace that there's roughly a 35% premium on price. Does that sound about right? And would you expect essentially the whole Indigo franchise, the 8 French included, to move over to Indigo plus Lightning — meaning, in other words, they'd be using Lightning? And does the higher price come along with the Lightning tubing? And I had something else to ask after.
Adam Elsesser
executiveOkay. Well, let me — you've packed 2 or 3 questions in there. So I'll attempt to jot them down, and I'll attempt to respond to each. If I skipped any, tell me, and then we'll get to your follow-up. First, I — as you're aware, and as you've come to learn about Penumbra and about me personally, from having covered us for a while, I usually don't race ahead of things and talk about products until it's more or less after the fact. And so your point that only 2 weeks have passed, and here I am saying these things, is very sharp; and the sole explanation for that is that my personality hasn't changed. So what's different? And that is how well this product has done. It is — our expectations for this product were very high. Larry, as you know, we've been at work on this for 4 years. The technology is pretty sophisticated, and we were pretty optimistic about what we believed we'd witness. But witnessing it during the first couple of weeks in the real world, and witnessing the success and the sheer enormous amounts of clot that we can remove from patients on the venous side, has honestly been somewhat remarkable; and I believe it has exceeded even our lofty expectations. So that's the reason I feel confident enough to say that. We've spoken with lots and lots of physicians who used it, gave it a try, and we heard how they reacted. And that's what prompted us to make those statements. Regarding price, which was the next portion of your question. There is obviously a — previously our tubing was merely tubing, and it went for a fairly small dollar amount, whereas this is now a far more sophisticated component that carries a higher price. But that price trade-off is accompanied by the fact that we're probably going to use considerably fewer separators, which were used in many of these venous cases. And that's kind of where we won't quite reach the same price premium you just described, because we'll see an overall decline in how many separators are used. So we priced this. We've discussed our pricing strategy. Our aim when it comes to pricing is always to keep this a profitable procedure for hospitals, so they can succeed in treating their patients and remain viable, and this carries on exactly the way we've always approached it. Thus, our pricing gives us a lot of confidence. That approach, as you are aware, has always been something we handle with care. Therefore, we never need to retreat; and this situation supports that approach perfectly, in precisely the manner we have consistently operated. And then, you mentioned having 1 or 2 additional questions.
Larry Biegelsen
analystYes. So to start with, JET 7, XTRA Flex, MAX — you've got that cleared, and I believe you mentioned a neuro access product, yet I didn't hear anything about how those are being rolled out. Then finally, regarding R&D spending, is this the new run rate? On an underlying basis it appears to be roughly $20 million per quarter — why such a big jump in R&D at this point? And is this the new run rate?
Adam Elsesser
executiveSure. On your first question about JET 7 MAX, which I did bring up, we've been doing the same work we do with any newly cleared product — evaluating it and making sure everything is good. The product is precisely what we hoped for. What I want everyone to understand — and I've said this before, I believe a number of times — is that certain products that are coming, this one included, matter on their own, but truly matter as part of a bigger piece of our long-term strategy. I said the same thing in my prepared remarks: what we're trying to do is change, at a fundamental level, the way stroke patients get treated, and MAX represents a major move in that direction, even if by itself it might not be as obvious as the longer-term picture, which I believe will come into sharper focus as we get nearer to — or rather, as we move into 2021; and regarding R&D spending, we're not saying anything today about whether this represents the new normal, beyond what we've already stated — that the raise we finished this quarter gave us comfort during a period when there is some uncertainty. Even without the raise, our intention was to move forward on this, but the additional funds gave us the confidence to commit that spending—with a particular emphasis on three projects that already existed inside the company, one being the real system. As we've noted previously, the pandemic created a chance for the real system to be utilized. The original real system—real one, to use a shorthand—comes into play when a therapist and patient are in the same physical location; starting in late March and through April, that arrangement became difficult for many patients. In response, CMS issued a new temporary order concerning reimbursement for what you might call tele rehab therapy sessions, and after that they sent out further notices on the subject. They might view this as something that sticks around long term. That creates the chance to enable many different capabilities for working with patients and therapists even when they aren't in the same place, plus letting therapists give assignments and operate on their own to speed up how quickly people get better. It likewise creates the chance to address kinds of medical conditions where no physical or occupational therapist is needed, yet which still have an enormous effect on patient health care or health and wellness. That's genuinely where the real investment opportunity sits — seizing on that demand, which is incredibly pressing in the market right now. And like I mentioned, the remaining 2 projects we've been developing are what gave us the confidence to keep putting money in, and in fact to speed them up. So I'd say the timing is good.
Bob Marcus
analystGreat. Could you provide a bit more detail on how the U.S. and international trends compare? I really appreciate that you separated peripheral and Neuro U.S. and international. I enjoy it when companies offer more rather than less detail and disclosure. But Adam, even if you take that 10% to 20% of revenues at distributors and simply assume none of it occurred during the quarter, you'd still see a pretty large gap in trends between international and U.S. How much of that, if you can say, came from the first half of the quarter versus the second? As we exit the quarter here, does international look more like the U.S.? And is there any other trend you can share to help us think about the future of U.S. versus international?
Adam Elsesser
executiveYes. Beyond what we've already said, I can't provide any sort of quantitative information. Obviously, in the U.S., there was a geographic difference between the first half of the quarter and the second half of the quarter, but on a whole quarter basis, the U.S. did relatively well. I guess there isn't anything — what I'm trying to respond to, I guess, is that there's nothing — no information is to be gotten here. Apart from what I called out regarding distributors versus our U.S. business, there's nothing about our international business. Our U.S. business is — was obviously strong. That story goes beyond just managing through the timing of the pandemic. And I guess that's the best way to answer the question. There's no underlying issue to uncover here. Both in the U.S. and international, the business has returned strongly. Our distributor markets, in the long term, I think, will be fine. So I guess I'm not sure what I — Maggie, maybe can provide some additional color.
Maggie Yuen
executiveMaybe what we could also mention is — correct, only the U.S.; plus the direct business in Europe, and in that case the results for the first half compared with the gain in the second half are fairly steady and even throughout. However, when we turn to revenue from international distributors, well, even looking back over time, those orders arrive in a rather erratic, uneven way. Therefore there is no — we are not able to conclude anything about the year's second half simply from how the first half or the second half performed.
Bob Marcus
analystAll right, and then perhaps to build on that, Adam, you mentioned that 3 products are being moved ahead in the pipeline using money from the equity raise. Real VR was one of them. I realize you won't reveal the remaining 2, but could you tell us whether these are near-term, medium-term, or long-term efforts? Do they belong inside the verticals you already have? Or are they fresh verticals, the way real VR was new for neuro and peripheral? And is there anything else you'd want to add?
Adam Elsesser
executiveSome of that gets a yes. Some of that gets a no. These are meaningful opportunities capable of benefiting a very large number of patients; and as you're aware, that is more or less how we evaluate the products we pursue, and each of these matches that description precisely. Meaningful opportunities that could benefit a very large number of patients.
Brandon Vazquez
analystBrandon here, filling in for Malgorzata. If I could just — when we look at the U.S., it seemed somewhat notable that the Vascular segment apparently faced somewhat milder challenges compared with the Neuro side. I suppose that stood out simply because one would think that contact with elective procedures on the Vascular side might have created a bit of a headwind, or an even larger headwind, versus Neuro. So I was wondering whether you might explain what you'd chalk that up to. Is it purely a matter of mix between elective and urgent? And then perhaps your outlook regarding what that implies for the remainder of 2020? And how should these segments perform moving ahead?
Adam Elsesser
executiveYes. Allow me to begin with a remark about the trend. We actually addressed this as well during the prior quarter, when we began noticing it in April at the time we reported our April figures. And I genuinely believe it boils down to the straightforward reality that, especially early in the quarter, the count of patients who'd suffered strokes — who were arriving — and once more, thoroughly covered not just in scientific literature but in mainstream media, did not arrive at the hospital. And they don't return. When that occurs, there's no way to make up for those or provide treatment afterward. Yet on the peripheral side, many of those — such patients are able to return and receive treatment; therefore a basic distinction exists in how those trend lines will ultimately appear, and I believe that's more or less what one would anticipate. And then, as we shift toward the point where people feel at ease heading to the hospital, we clearly observed that favorable trend line during the latter half of the quarter. However, my concern is precisely what's occurring in the broader communities, in the U.S; as well as other markets, given the pandemic and the speeding up of cases in the U.S; and the renewed surge of cases in certain other markets where they'd succeeded better at containing it. So that's the source of some uncertainty as we move forward. Apart from what all of us already know from reading and hearing the news, we possess no further insight that could offer anything like guidance or a perspective looking ahead. Naturally, if we're able to keep people informed and sustain public awareness that a hospital visit is safe, we'd anticipate stroke figures to stay robust. But should that shift and people begin feeling otherwise, then those figures could be and would be affected. The peripheral figures enjoy that extra — the upside of witnessing a portion of that business return in June and afterward, as we mentioned, persist into July.
Brandon Vazquez
analystUnderstood, that helps. And staying with Vascular for a moment — have your sales reps managed to get back into those accounts? I'm wondering how the training push is going and what that means for growth ahead. First, can you bring new physicians up to speed? In other words, is it possible to see growth in the second half of the year coming from new physicians? And can you genuinely continue building that market, given that it takes a fair amount of market development work?
Adam Elsesser
executiveYes, that's a terrific question. What I'd say is that across the stretch from June through July, quite a few reps succeeded in getting back into hospitals. Certain regions of the country definitely turned more challenging and stretched once the virus accelerated. Even so, up to this point that hasn't seriously constrained us, especially when it comes to rolling out Lightning 12. That said, we remain careful about extending what we've observed so far into the second half of the year, simply because of how things are evolving and the reports you keep hearing; even with that caveat, it hasn't held us back yet. And for the majority of people, using this product is — if you're already a user of this product and the only change is that you're adding Lightning, it doesn't truly demand extra in-person training; it's a nice thing to have, and we're glad to provide it, but you could manage without it. That's partly what our virtual launch amounts to, so to speak. As for new physicians who have never used it, they could certainly manage as well, though we'd want to arrange some in-person education or training for them where we can.
Joanne Wuensch
analystThere are 2 things I want to ask, and I'll put them both out there at once. A factor behind growth in the U.S. stroke market involved new guidelines being picked up region by region, or state by state. It's obvious to me that all states have plenty of other things pulling at their attention. Still, have any further discussions come up around that kind of subject? My second one leans toward the financial side. If I understood you correctly, gross margins for the third quarter should land close to what we saw in the second quarter. Could you verify that? And after that, what's the way to think about getting that metric speeding up again?
Adam Elsesser
executiveOf course. I'll take the first portion, then hand the gross margin piece over to Maggie. Your read, I believe, is broadly accurate — at the moment state legislatures have their hands full with many matters other than stroke triage. Clearly, they're dealing with issues tied to the pandemic, joblessness, schools reopening, and more. An update came to us not long ago from the organization spearheading this campaign, and a few favorable steps are still underway, though likely somewhat slower than usual, in Massachusetts, Ohio, Pennsylvania. Even so, my expectation is that this state-by-state effort will ease off for a while as we get through the pandemic. That said, it doesn't put it past that window. Maggie, go ahead and take the gross margin question.
Maggie Yuen
executiveJoanne, so as we think about gross margin — well, first off, gross margin remains tied to how much volume gets absorbed. If both revenue and volume go up, we can leverage our fixed costs more effectively. That said, a few other things come into play. During this quarter, we made investments and built up inventory to get ready for new product launches in Q3. As a result, part of the under-absorbed overhead for this quarter sits in inventory and will show up in this quarter. Another consideration: even as we manage demand, we're still making appropriate investments in efficiency and productivity at our new Roseville facility. So a few of these investments might affect margin in the near term, but every one of them positions us for stronger margin expansion down the road. So it's more of a future — a short-term perspective.
Jee Hamlyn-Harris
executiveAppreciate it, operator. Our management team and I want to say once more how grateful we are that you're all here with us today, and that you've shown such interest in Penumbra. We're eager to bring you up to speed on our call for the third quarter.
Operator
operatorThis concludes today's conference call. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.